Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
Dr. Felix uses molecular, biochemical, cellular and in vivo methods to investigate the pathobiology of leukemias with KMT2A (MLL) translocations. Leukemias with these translocations affect infants and young children or occur as a complication of type II topoisomerase (TOP2) poison chemotherapies used for anti-cancer treatment. She aims to develop better treatment and prevention approaches for these leukemias, which have a poor prognosis.
Dr. Tan studies transcriptional regulation during normal development and disease. This involves the interplay of multiple transcription and epigenetic factors in a 3D chromosomal environment. Using experimental genomics and computational modeling, Dr. Tan investigates transcriptional regulatory networks underlying embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.
The Gadue Laboratory studies human pancreatic and hematopoietic development and associated diseases using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells. The lab has devoted much of its research efforts on directed differentiation and CRISPR-based genome engineering of stem cells and is using this system for the study and development of treatments for diabetes and blood disorders.
The Tan Laboratory studies the fundamental question of transcriptional regulation during normal development and disease. It involves a complex interplay of multiple transcription factors and epigenetic factors in the context of a three-dimensional chromosomal environment. Using experimental genomics and computational modeling, the lab has been studying transcriptional regulatory networks underlying embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.
The Blobel Lab investigates the fundamental mechanisms involving transcription factors, chromatin regulators, and higher order chromatin, gearing its basic science discoveries toward genetic and epigenetic treatment modalities.
The Behrens Lab is interested in the pathogenesis and treatment of cytokine storm syndromes, including the hemophagocytic syndromes Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS). These are uniquely pediatric immunologic conditions that result in severe systemic inflammation and death if unrecognized and untreated.